Mumbai, April 26 -- Zydus Lifesciences announced that the USFDA conducted a surveillance inspection at the group's API Unit, located at Dabhasa in Gujarat. The inspection was conducted from April 21st to 25th, 2025.
The inspection concluded with 6 observations and none of them were related to Data Integrity. The company is confident to address the observations expeditiously.
Published by HT Digital Content Services with permission from Capital Market....
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.